RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $18.17 Consensus Target Price from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned an average recommendation of “Hold” from the ten brokerages that are presently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $18.17.

Several research analysts have recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. UBS Group reduced their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th.

RAPT Therapeutics Price Performance

Shares of RAPT opened at $1.89 on Monday. The company has a market capitalization of $65.97 million, a P/E ratio of -0.62 and a beta of 0.33. RAPT Therapeutics has a one year low of $1.64 and a one year high of $27.35. The business’s 50 day simple moving average is $1.97 and its 200-day simple moving average is $3.68.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.03. On average, sell-side analysts anticipate that RAPT Therapeutics will post -2.73 EPS for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in shares of RAPT Therapeutics during the 1st quarter valued at $97,000. EntryPoint Capital LLC bought a new stake in shares of RAPT Therapeutics during the 1st quarter valued at $161,000. Denali Advisors LLC bought a new stake in shares of RAPT Therapeutics during the 1st quarter valued at $293,000. XTX Topco Ltd bought a new stake in shares of RAPT Therapeutics during the 2nd quarter valued at $108,000. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of RAPT Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after acquiring an additional 3,824 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.